ClinicalTrials.gg
RecruitingNCT05994586Updated Aug 16, 2023

The Efficacy of AP029 Mix in Patients With Impaired Carbohydrate Metabolism

An interventional study of AP029 mix and Placebo in Diabetes in Adolescence and PreDiabetes, sponsored by AronPharma Sp. z o. o.. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-16.

Sponsored by AronPharma Sp. z o. o. · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Prediabetic State with a site in Poland — 6 open to participants now, 6 under way, none of them phase 3. Prediabetic State · Poland.

Started
2023
the only one that year
No phase
6 of 11
2 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
AronPharma Sp. z o. o.

Among the 11 studies in Prediabetic State with a site in Poland, this one is the only one that started in 2023, is one of 6 with no phase, and was the 9th registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

6 of the 11 studies in Prediabetic State with a site in Poland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Prediabetic State with a site in Poland, or all of them as a file.
02

Study summary

The aim of the study is to demonstrate that a daily supplementation of AP029 Mix: I) has a positive effect on reducing side effects of metformin, while enhancing the therapeutic effect of metformin; II) normalizes prediabetes biomarkers in order to prevent further progression into diabetes.

Read the detailed description

Randomized, double-blind, cross over study conducted under medical supervision on 1) group of 20 patients with type II diabetes and 2) group of 10 patients with prediabetes.

Study design: 2 months of AP029 supplementation, 1 month wash-out, 2 months of placebo intake. Patients will attend 4 visits. On each visit, the following parameters are analyzed: level of glucose, insulin, HbA1c, hsCRP lipid panel (total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), HDL) and inflammatory and oxidative stress markers. In addition, a questionnaire of symptoms associated with metformin intake will be conducted

03

Conditions studied

  • Diabetes in Adolescence
  • PreDiabetes

Keywords

  • Type II diabetes
  • Prediabetes
  • Disorders of Carbohydrate Metabolism
  • Chokeberry
  • Elderberry
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for type II diabetes:

  • Women and men, 18-75 years old
  • Patients diagnosed with type II diabetes mellitus
  • Patients on metformin treatment up to 5 months
  • 20-35 kg/m2
  • Signed

Inclusion Criteria for prediabetes:

  • Women and men, 18-75 years old
  • BMI 20-35 kg/m2
  • Fasting blood glucose levels between 100 mg/dl and 125 mg/dl (5.6-6.9 mmol/l)
  • Signed informed consent

Exclusion Criteria for type II diabetes:

  • Patients diagnosed with type I diabetes
  • Patients receiving insulin or other anti-diabetic medications
  • Women who are pregnant, planning to become pregnant during the study, or breastfeeding
  • Surgery within the last 6 months
  • Intake of dietary supplements containing plant extracts rich in polyphenols and anthocyanins
  • Intake of supplements containing: white mulberry, chromium, berberine
  • Patients receiving glucocorticosteroids,
  • Oncological disease, disease, severe liver dysfunction, tuberculosis, leukemia, multiple sclerosis, AIDS, rheumatoid arthritis, organ transplant
  • Acute inflammation (C-reactive protein >20mg/dl)

Exclusion Criteria for prediabetes:

  • Patients diagnosed with type I, II, LADA diabetes
  • Patients receiving insulin or other anti-diabetic medications
  • Women who are pregnant, planning to become pregnant during the study, or breastfeeding
  • Surgery within the last 6 months
  • Intake of dietary supplements containing plant extracts rich in polyphenols and anthocyanins
  • Intake of supplements containing: white mulberry, chromium, berberine
  • Patients receiving glucocorticosteroids, immunosuppressants
  • Oncological disease, autoimmune disease, severe liver dysfunction, tuberculosis, leukemia, multiple sclerosis, AIDS, rheumatoid arthritis, organ transplant
  • Acute inflammation (C-reactive protein >20mg/dl)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    AP029 mix - type II diabetes

    Patients with type II diabetes receiving metformin for up to 5 months

    Dietary Supplement: AP029 mix

  • Experimental
    AP029 mix - prediabetes

    Patients with pre-diabetic

    Dietary Supplement: AP029 mix

  • Placebo comparator
    Placebo - type II diabetes

    Patients with type II diabetes receiving metformin for up to 5 months

    Other: Placebo

  • Placebo comparator
    Placebo - prediabetes

    Patients with pre-diabetic

    Other: Placebo

Interventions

  • Dietary supplementAP029 mix

    Polyphenol-rich plant extracts Twice a day

  • OtherPlacebo

    Twice a day

06

What researchers measure

Primary outcomes

  1. Glucose level

    Comparison of glucose level

    Time frame: Baseline, 2 months, 3 months, 5 months

  2. Insulin level

    Comparison of insulin level

    Time frame: Baseline, 2 months, 3 months, 5 months

  3. Discomfort related to metformin side effects

    Based on questionnaire

    Time frame: Baseline, 2 months, 3 months, 5 months

Secondary outcomes

  1. Lipid panel (total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), HDL)

    Comparison of lipid panel markers

    Time frame: Baseline, 2 months, 3 months, 5 months

  2. hsCRP level

    Comparison of hsCRP level

    Time frame: Baseline, 2 months, 3 months, 5 months

  3. HbA1c level

    Comparison of hbA1c level

    Time frame: Baseline, 2 months, 3 months, 5 months

07

Study locations

1 of 1 sites recruiting
  • Pomorskie Centrum Reumatologiczne im. dr Jadwigi Titz-Kosko
    Sopot, 81-820, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Nov 2023, 6 months after the start.

Of 46 industry-sponsored interventional studies with no phase under Prediabetic State, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's planned 6 months is below that.

Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Aug 16, 2023
StartActual
May 25, 2023
Primary completionEst.
Nov 26, 2023
CompletionEst.
Nov 26, 2023
Last update
Aug 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05994586
Lead sponsor
AronPharma Sp. z o. o.
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
May 25, 2023
Primary completion
Nov 26, 2023 (estimated)
Completion
Nov 26, 2023 (estimated)
Last update
Aug 16, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion